About International Stem Cell Corp.
International Stem Cell Corp. is a company based in Carlsbad (United States) founded in 2001 by William Adams. International Stem Cell Corp. has raised $21.81 million across 6 funding rounds. The company has 32 employees. International Stem Cell Corp. offers products and services including Stem Cell Pipeline and Manufacturing Science. International Stem Cell Corp. operates in a competitive market with competitors including Kriya Therapeutics, Annexon, NuVasive, Aldeyra and Ensoma, among others.
- Headquarter Carlsbad, United States
- Employees 32
- Founders William Adams
- Stage Public
- SectorsHealthcare
- Website internationalstemcell.com
- Social LinkedIn X Facebook
- Legal Name International Stem Cell Corp.
- Annual Revenue$9.1 M (USD)0.17as on Dec 31, 2025
- Net Profit-$418 K (USD)-100as on Dec 31, 2025
- EBITDA-$48 K (USD)-134.29as on Dec 31, 2025
- Total Equity Funding$21.81M (USD)
in 6 rounds
- Latest Funding Round$6.3M (USD), Post-IPO
Mar 2016
- Employee Count32
Products & Services of International Stem Cell Corp.
International Stem Cell Corp. offers a comprehensive portfolio of products and services, including Stem Cell Pipeline and Manufacturing Science.
Develops stem cell therapies for research and medical applications
Provides biotechnology manufacturing and development services
Funding Insights of International Stem Cell Corp.
International Stem Cell Corp. has successfully raised a total of $21.81M across 6 strategic funding rounds. The most recent funding activity was a Post-IPO round of $6.3 million completed in March 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $21.81M
- Total Rounds 6
- Last Round Post-IPO — $6.3M
- First Round $20M
(Nov 2006)
All 6 funding rounds of International Stem Cell Corp. with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2016 | $6.3M | Post-IPO | – | – | – |
| Jan 2016 | $4.7M | Post-IPO | – | – | – |
| Oct 2014 | $2.5M | Post-IPO | – | – | – |
| Mar 2012 | $5M | Post-IPO | – | – | – |
| Dec 2006 | $1.81M | Series B | – | – | – |
| Nov 2006 | $20M | Series B | – | – | – |
People of International Stem Cell Corp.
1 people are tracked at International Stem Cell Corp. (1 in leadership); the tracked headcount is 32.
| Name | Role | Group |
|---|---|---|
William Adams | Co-Founder | Leadership |
Complete people profiles for International Stem Cell Corp.
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of International Stem Cell Corp.
International Stem Cell Corp. is a publicly listed company on the OTC with ticker symbol ISCO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date25 Nov 2009
- Listed onNASDAQ: ISCO
- Listed entityInternational Stem Cell Corp.
- Exchange sectorHealth technology
- ISINUS4603782016
- Share price$0.27 (-6.99% on the day) · 2026-10-08
- Market capitalisation$2.1M
- EPS (diluted, trailing year)$-0.08
- Volume (last session)802
Financials of International Stem Cell Corp.
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $9.1M | -$418,000 | -$48,000 |
| 2024 | $9.1M | -$209,000 | $140,000 |
| 2023 | $7.8M | -$131,000 | -$469,000 |
| 2022 | $8.2M | -$331,000 | $176,000 |
| 2021 | $7.2M | -$899,000 | -$1.1M |
Detailed financial statements for International Stem Cell Corp.
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of International Stem Cell Corp.
4 dated milestones of International Stem Cell Corp. across 15 years, from founding to its latest funding, stage changes and deals.
- Founded International Stem Cell Corp. is founded.
- Funding First funding round of $20.0M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $6.3M.
Competitors of International Stem Cell Corp.
International Stem Cell Corp. operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Kriya Therapeutics, Annexon, NuVasive, Aldeyra and Ensoma, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| annexonbio.com | 2011 | San Francisco, United States | $256M | 80 | Developer of antibodies to treat complement-mediated neurodegenerative diseases | |
| nuvasive.com | 1997 | San Diego, United States | $54.1M | 2,450 | Smart surgical devices for spinal surgery are developed. | |
| aldeyra.com | 2004 | Lexington, United States | $4.79M | 30 | Drug candidates for immune-mediated diseases are developed by Aldeyra. | |
| ensoma.com | 2019 | Boston, United States | $205M | 52 | Provider of in vivo stem cell modification technologies and vector-based drug delivery tool | |
| nicox.com | 1996 | Valbonne, France | $271.01M | – | Nitric oxide-based therapeutics for glaucoma and eye conditions are developed. | |
| gyroscope.cc | 2016 | San Francisco, United States | – | – | Mobile SDK developed for app engagement and monetization strategies. | |
| meiragtx.com | 2015 | New York, United States | – | 358 | Gene therapies for ocular and neurodegenerative diseases are developed. | |
| perceivebio.com | 2021 | San Francisco, United States | $78M | – | Developer of therapeutics to treat diabetes and eye diseases |
Detailed competitors of International Stem Cell Corp.
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of International Stem Cell Corp.
The website of International Stem Cell Corp. (internationalstemcell.com) receives about 2.6K visits a month.
- Monthly visits2.6K
▲ 20.5% vs previous month
Websites whose visitors overlap most with International Stem Cell Corp.. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| biolamina.com | 100% | 9.1K | #2,560,936 | View details | |
nhnscr.org | nhnscr.org | 100% | – | – | – |
stemcelldaily.com | stemcelldaily.com | 100% | – | – | – |
stemcell.childrenshospital.org | stemcell.childrenshospital.org | 100% | – | – | – |
Latest news on International Stem Cell Corp.
Complete news archive for International Stem Cell Corp.
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to International Stem Cell Corp.
10 companies that operate in the same segment as International Stem Cell Corp. (Cell Therapy), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
CAR T-cell and T-cell receptor immunotherapies for cancer are developed. | 2013 | Seattle, Washington, United States | USD 316.67 M | – | 520 | |
CAR-T and TIL immunotherapies for solid tumors are developed. | 2018 | San Francisco, California, United States | USD 493 M | USD 36 K | 300 | |
T-cell-based immunotherapies for cancer treatment are developed. | 2000 | Tubingen, Baden-wurttemberg, Germany | USD 236.4 M | USD 54.47 M | 423 | |
Engineered T-cell immunotherapies are developed for cancer and auto-immune diseases. | 2015 | London, England, United Kingdom | USD 181.37 M | USD 75.56 M | 647 | |
Smart surgical devices for spinal surgery are developed. | 1997 | San Diego, California, United States | USD 54.1 M | – | – | |
Genetically engineered cell therapies are developed for multiple disorders. | 2018 | Seattle, Washington, United States | USD 821 M | – | 194 | |
Provider of bio-artificial pancreas for Type 1 Diabetes treatment | 2015 | Cambridge, Massachusetts, United States | USD 158 M | – | 58 | |
T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | 2011 | San Francisco, California, United States | USD 36.13 M | – | 36 | |
Developer of immune cell therapies | 2019 | San Francisco, California, United States | USD 631.16 M | – | 178 | |
Cue Biopharma is focused on developing immunotherapy solutions. | 2015 | Cambridge, Massachusetts, United States | USD 10 M | USD 27.47 M | 41 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about International Stem Cell Corp.
International Stem Cell Corp. was founded in 2001 and raised its 1st funding round 5 years after it was founded.
International Stem Cell Corp. is headquartered in Carlsbad, United States. It is registered at Carlsbad, California, United States.
International Stem Cell Corp. is a funded company, having raised a total of $21.81M across 6 funding rounds to date. The company's 1st funding round was a Series B of $20M, raised on Nov 2006.
International Stem Cell Corp. has 32 employees.
Annual revenue of International Stem Cell Corp. is $9.1M as on Dec 31, 2025.
Regenerative medicine solutions for ophthalmology, neurology and liver disease. Its proprietary technology to develop uses parthenogenesis which uses unfertilized eggs to circumvent immune-rejection. The company is currently exploring stem cell therapies for Parkinsons disease, ischemic stroke, metabolic liver disease, retinal blindness and corneal blindness. In addition, ISCO also maintains a stem cell bank for non-embryonic histocompatible human stem cells for research and commercial use.
International Stem Cell Corp. offers Stem Cell Pipeline and Manufacturing Science.
Yes, International Stem Cell Corp. is publicly traded on OTC under the ticker symbol ISCO.
International Stem Cell Corp. operates through International Stem Cell Corporation.